bis
Market Research Report

A quick peek into the report

CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market - A Global and Regional Analysis

Focus on Indication, Therapy, and Region - Analysis and Forecast, 2025-2035
This report will be delivered in 7-10 working days.

 
Some Faq's

Frequently Asked Questions

The global CAR T-cell therapy for non-hodgkin's lymphoma market is led by prominent pharmaceutical companies such as Allogene Therapeutics, Autolus Therapeutics, Bristol Myers Squibb, Crispr Therapeutics, Gilead Sciences, Imugene, Janssen Biotech, Miltenyi Biomedicine, Novartis AG and SOTIO.

Trends:
•    Expansion of approved indications
•    Earlier line of therapy integration
•    Emergence of allogeneic CAR T-cells
•    Advancements in manufacturing platforms

Driver:
•    High unmet clinical need in relapsed/refractory NHL
•    Strong clinical efficacy and durable responses
•    Regulatory support and accelerated approvals

•    High-cost costs of advanced therapies
•    Complex and lengthy manufacturing process
•    Severe and potentially life-threatening side effects
•    Limited availability of treatment centers

•    Expansion into earlier lines of therapy
•    Development of next-generation CAR constructs
•    Adoption of allogeneic (Off-the-Shelf) CAR T therapies